Note: Descriptions are shown in the official language in which they were submitted.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
OXIDATION-REDUCTION SENSITIVE
GREEN FLUORESCENT PROTEIN VARIANTS
STATEMENT REGARDING GOVERNMENT FUNDING
Aspects of the research leading to this disclosure were supported by the
following
government agencies under the identified grants: National Institutes of Health
Training Grant for
GTH I/D Serial No.: GM07759-22; and National Institutes of Health Grant I/D
Serial No.:
GM42618-10. The government may have certain rights in this invention.
FIELD
The present disclosure relates to the field of genetic engineering, and in
particular to green
fluorescent protein (GFP) mutants that can be used to detect oxidation-
reduction state, or a change in
oxidation-reduction state.
BACKGROUND
The green fluorescent protein (GFP) from the Pacific Northwest jellyfish,
Aequorea victoria,
has been used extensively in molecular and cell biology as a fluorescent
marker. It is a 238 amino
acid protein that generates its own fluorescent chromophore. The spontaneous
generation of the
chromophore is achieved by cyclization of the internal Ser65-Tyr66-G1y67
sequence followed by
oxidation of Tyr 66 in the presence of molecular oxygen (Heim et al., Proc.
Natl. Acad. Sci. USA
91:12501-12504, 1994). The overall fold of the protein consists of an 11-
stranded (3-barrel capped by
a-helices at both ends and contains a coaxial a-helix from which the
chromophore is generated
(Brejc et al., Proc. Natl. Acad. Sci. USA 94:2306-2311, 1997; Ormo eta!.,
Science 273:1392-1395,
1996; Yang et al., Nat. Biotech. 14:1246-1251, 1996). GFP is unique among
light emitting proteins,
because it does not require the presence of any cofactors or substrates for
the production of green
light.
Wild-type GFP has absorption maxima at 398 and 475 nun (Morise et al.,
Biochemistry
13:2656-2662, 1974). Excitation at either of these wavelengths leads to
emission of green light at
508 nm (Morise et al., 1974). The usefulness of GFP has been greatly enhanced
by the availability of
mutants with a broad range of absorption and emission maxima (Heim et a!.,
Proc. Nat!. Acad. Sci.
USA 91:12501-12504, 1994; Oruro et al., Science 273:1392-1395, 1996). These
mutants have made
possible multicolor reporting of cellular processes by allowing for the
simultaneous observation of
two or more gene products labeled with different colored GFP variants (Rizzuto
et a!., Curr. Biol.
6:183-188, 1996). In addition, fluorescence resonance energy transfer (FRET)
experiments using
different colored GFP's have been used to study protein-protein interactions
in vivo (Heim et al.,
Curr. Biol. 6:178-182, 1996; Mitra et al., Gene 173:13-17, 1996).
More recently, GFP variants have been shown to be sensitive to pH (Wachter et
a!.,
Biochemistry 36:9759-9765, 1997; Elsliger et al., Biochemistry 38:5296-5301,
1999). As a
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
2
consequence, they have been used as noninvasive intracellular pH indicators.
For instance, Kneen et
al. employed the GFP mutant S65T/F64L to determine the pH of the cytoplasm of
CHO and LLC-
PKI cell lines (Kneen et al., Biophys.J. 74:1591-1599, 1998). Since GFP is
genetically encoded, it
can be specifically targeted to various subcellular compartments, which is a
task not possible with
small molecule fluorescent dyes (Llopis et al., Proc. Natl. Acad. Sci. USA
95:6803-6808, 1998).
Therefore, Llopis and co-workers used the GFP variant S65G/S72A/T302Y/H23IL,
which has an
increased pKa, to measure the alkaline pH of mitochondria, golgi, and the
cytosol of HeLa cells and
rat neonatal cardiomyocytes (Llopis et al., 1998). These reports were the
first to show that GFP
variants could be used as biosensors and not just simple fluorescent markers.
However, more
recently GFP has been shown to be sensitive to halide ions and through a
fusion with calmodulin,
GFP's fluorescence can also vary in response to calcium ion concentration
(Wachter et al., Curr.Biol.
9:R628-R629, 1999; Miyawaki et al., Proc. Natl. Acad. Sci. USA 96:2135-2140,
1999).
Oxidation-reduction (redox) processes are very important in living organisms.
The
formation of disulfide bonds during protein folding relies upon a well
maintained redox buffering
system of glutathione and oxidized glutathione (Carothers et al., Arch.
Biochem. Biophys. 268:409-
425, 1989). There also exists a thioredoxin-like family of enzymes that
catalyze the formation and
isomerization of disulfide bonds in proteins (Debarbieux and Beckwith, Cell
99:117-119, 1999). In
addition, redox signaling during apoptosis has been implicated in activating
mitochondrial
permeability transition, leading to cytochrome c release (Hall, Eur. J. Clin.
Invest. 29:238-245, 1999).
Redox changes in the form of cellular oxidation have also been suggested to be
a final step in the
apoptotic process leading to degradation of apoptotic bodies (Cai and Jones, J
Bioenerg. Biomemb.
31:327-334, 1999). Given the importance of in vivo processes such as protein
folding and apoptosis
that are dependant upon redox status, a non-invasive, convenient method for
studying redox changes
within living cells is needed.
Current methods of determining in vivo redox status have many limitations.
Many present
techniques require cells to be harvested before their contents can be
analyzed. This type of procedure
is not only very invasive but is also not a very accurate measure of the in
vivo state of the cells.
Moreover, it would be impossible with this technique to monitor redox changes
within the same cell
over a period of time. Recently, Keese et al. (Keese et al., FEBSLett. 447:135-
138, 1999) have
developed an indicator of redox state in which glutathione reductase crystals
were microinjected into
the cytosol of human fibroblasts, and by detecting a color change of the
crystals, they were able to
determine the redox potential of the cytosol to be more reducing than -0.270
V. While this method
may allow redox determination within single living cells, the cumbersome
nature of the technique is
still a major drawback. The most reasonable protocol for determining redox
status is probably still
that of Hwang et al. (Hwang et al., Science 257:1496-1502, 1992). They
employed the tetrapeptide
N-Acetyl-Asn-Tyr-Thr-Cys-NH2 to measure the ratio of thiol to disulfide in the
cytosol and secretory
pathway of cultured cells. They concluded that the cytosol is more reducing
than the secretory
pathway with an approximate redox potential of -0.221 to -0.236 V for the
cytosol compared to -
0.170 to -0.185 V for the secretory pathway. However, this method still
required harvesting of the
CA 02440592 2010-08-17
86479-1
3
cells and like all the other methods, it is very labor intensive. Moreover,
this technique determined
redox potentials based only upon the ratio of reduced glutathione (GSH) to
oxidized glutathione
(GSSG), potentially ignoring other redox buffering components.
SUMMARY OF THE DISCLOSURE
To overcome disadvantages of available methods for determining redox status in
cells, GFP
mutants (also referred to as redox sensitive GFP (rosGFP) variants) have been
designed and are
described herein, which can detect or "sense" changes in oxidation-reduction
potentials. The rosGFP
variants have been engineering to have two cysteine amino acids near the
chromophore and within
disulfide bonding distance of each other.
Examples of the provided GFP variants have ratiometric dual-excitation
fluorescent
properties as a function of redox state, with apparent redox potentials of -
0.272 to -0.299 V.
Specific embodiments include rosGFP mutants that differ from wild-type GFP in
that they
comprise at least the following amino acid substitutions:
(a) S147C/Q204C
(b) S65T/S I47C/Q204C
(c) N I49C/S202C
(d) S65T/N149C/S202C
(e) SI47C/N149C/S202C/Q204C
(f) S65T/S 147C/N 149C/S202C/Q204C
The rosGFP mutants that include the S65T substitution are sensitive to pH as
well as redox status.
Particular provided mutation proteins include those referred to herein as
rosGFPI, rosGFP2,
rosGFP3, rosGFP4, rosGFP5, and rosGFP6.
Also provided are nucleic acid molecules encoding rosGFPs, including the
specific listed
rosGFPs. Optionally, these nucleic acid molecules can be functionally linked
to expression control
sequence(s) (such as a promoter), and/or integrated into a vector. Nucleic
acid molecules encoding a
rosGFP can be used to transform host cells (such as bacterial, plant, or
animal cells); such
transformed cells are also provided.
The disclosure also provides methods of using rosGFPs to analyze the redox
status of a cell,
or a subcellular compartment within a cell. In certain embodiments, both the
redox status and pH of
the cell (or subcellular compartment or other environment) are monitored
concurrently.
CA 02440592 2010-08-17
86479-1
3a
In one aspect, the present invention relates to an isolated nucleic
acid molecule encoding a mutant green fluorescent protein (GFP) with a
fluorescence spectrum that is sensitive to redox status, wherein the mutant
GFP
shares at least 90% sequence identity with SEQ ID NO: 1 and wherein mutations
include: a) a cysteine at one or both of the residues corresponding to 147 or
149 of
SEQ ID NO: 1 and b) a cysteine at one or both of the residues corresponding
to 202 or 204 of SEQ ID NO: 1.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a fluorescence spectra graph, which shows how the
fluorescence of rosGFP2 varies in response to changes in redox potential. The
spectra show two excitation peaks, one near 400 nm and the other at about
490 nm, with a clear isosbestic point separating them.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
4
Figure 2 shows the titration of rosGFP2 with dithiothreitol. The apparent
redox potential is
-0.279 volts.
Figure 3 is a graph showing the in vivo redox changes in fluorescence
intensity of rosGFP2,
in response to the addition of vitamin K3. After 30 total minutes, the
addition of dithiothreitol elicits
the opposite response as indicated by the reduced ratio.
Figure 4 shows an SDS-PAGE analysis that reveals the intracellular disulfide
linkage in
rosGFP2. Lanes 1 - 6, control (C48S/S65T) and lanes 8 - 13 rosGFP2 were
incubated with I gM
CuC12 (with or without 2 mM N-ethylmaleimide; lanes 2, 3, 11, 12) or with 1 mM
DTT (with or
without 2 mM N-ethylmaleimide; lanes 5, 6, 8, 9). Lane 7 shows approximate
molecular weights in
kDa. Lanes 4 and 10 were empty.
Figure 5. Absorbance and fluorescence excitation spectra of rosGFP2 at various
redox
states. The absorbance spectra (A) show the conversion of the neutral (band A;
400 nm) to the
anionic (band B; 490 nm) chromophore species over time in the presence of 1 mM
DTT. Band A is
maximized under oxidizing conditions, whereas band B is favored under reducing
conditions.
Fluorescence spectra (B) were collected at various redox potentials and also
show the interconversion
of chromophore charge states. Absorbance and fluorescence spectra were both
normalized to the
intensity of the fully reduced protein.
Figure 6. Fluorescence excitation spectra of rosGFP4 as a function of redox
potential. The
entire spectrum (A) shows the redox potential dependence on the excitation
spectra of rosGFP4.
Expanded the region around 400 nm (B), reveals a well resolved isosbestic
point. Fluorescence
intensity values were normalized to the maximum intensity at E0' -0.320 V and
emission was
monitored at 510 nm.
Figure 7. Fluorescence excitation spectra of rosGFP6 as a function of redox
potential.
Fluorescence intensity values were normalized to the maximum intensity at E0' -
0.310 V and
emission was monitored away from the peak at 535 nm.
Figure 8. Absorbance and fluorescence excitation spectra of oxidized rosGFP2
as a
function of pH. Absorbance scans (A) were taken on samples of rosGFP2
containing 0.5 M CuC12
at the indicated pHs. These samples were then diluted in the same buffer and
their fluorescence
excitation spectra (B) were collected. Fluorescence intensity values were
normalized to the
maximum intensity at pH 9.0 and emission was monitored at 510 nm.
Figure 9. pH titration of oxidized and reduced rosGFP2. Absorbance values at
490 nm
(band B) were plotted versus pH for oxidized (A) and reduced (B) rosGFP2. The
data were then
fitted to a titration curve with a single pKa value.
Figure 10. Absorbance and fluorescence excitation spectra of reduced rosGFP2
as a
function of pH. Absorbance scans (A) were taken on samples of rosGFP2
containing 1 mM DTT at
the indicated pHs. These samples were then diluted in the same buffer and
their fluorescence
excitation spectra (B) were collected. Fluorescence intensity values were
normalized to the
maximum intensity at pH 9.0 and emission was monitored at 510 nm. Absorbance
readings around
280 nm are greatly altered due to the presence of DTT and thus are not shown.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
Figure 11. Fluorescence excitation spectra of rosGFP1 at various redox
potentials.
Fluorescence intensity values were normalized to the maximum intensity at Eo' -
0.320 V and
emission was monitored at 510 nm.
Figure 12. Fluorescence excitation spectra of rosGFP3 at various redox
potentials. The
5 entire spectrum (A) shows the redox potential dependence on the excitation
spectra of rosGFP3.
Expanded the region around 405 nm (B), reveals the existence of an isosbestic
point. Fluorescence
intensity values were normalized to the maximum intensity at E0' -0.330 V and
emission was
monitored at 510 nm.
Figure 13. Fluorescence excitation spectra of rosGFP5 at various redox
potentials.
Fluorescence intensity values were normalized to the maximum intensity at E0' -
0.330 V and
emission was monitored off the peak at 535 nm.
Figure 14. A fluorescence excitation ratio results in the cancellation of pH
artifacts. In the
oxidized (A) or reduced (B) state, a ratio of fluorescence intensities at
various excitation wavelengths
of rosGFP2 is independent of pH.
Figure 15. Dual-emission characteristics of rosGFP2. Excitation at 400 nm
results in
emission peaks centered near 450 and 510 nm, which have an opposite response
to pH changes.
Figure 16. A fluorescence emission ratio results in the cancellation of redox
potential
changes on pH determination. The fluorescence emission spectra (A) of rosGFP2
were collected at
various redox potentials (ratios of DTT and DTToX) and at a constant pH of
6Ø Plotting the ratio of
the two emission peaks results in a constant ratio over a large range of redox
states (B). The dashed
lines in B represent the maximum and minimum ratios to illustrate the possible
dynamic range of
rosGFP2 as a function of pH.
Figure 17. A fluorescent micrograph showing the reticular localization pattern
of rosGFPI
expressed in the mitochondrial matrix of an in vitro cultured HeLa cell, via
fusion at the DNA level
to the mitochondrial targeting sequence of the Eja subunit of pyruvate
dehydrogenase.
Figure 18. Response of rosGFPl to H202 and DTT induced redox potential changes
in
HeLa cell mitochondria. H202 and DTT were added at the indicted time points to
a final
concentration of 1 mM and 30 mM, respectively. The Fluorescence Intensity axis
corresponds to the
individual wavelengths, whereas the Ratio 400/480 axis corresponds to the
ratio of the two
wavelength channels.
Figure 19. NADH-dependent reduction of rosGFPl via lipoamide dehydrogenase.
Each
bar represents the percent reduction of oxidized rosGFPI by 1-2 gL LDH, 1 mM
lipoate, 1 mM
NADH, and/or 1 mM DTT. Samples were equilibrated at 22 C for one hour after
which the
fluorescence excitation was scanned from 325 to 525 nm. Percent reduction
values were determined
by the fluorescence at 490 nm with 100% corresponding to reduction by DTT.
Figure 20. Fluorescence excitation spectra of rosGFP2 at varying
concentrations of DTT1ed
and DTToX. Fluorescence emission intensity was monitored at 510 nm and
normalized to the
maximum intensity of the fully reduced spectrum (solid line).
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
6
Figure 21. Redox equilibrium titration of rosGFP2 with dithiothreitol. The
relative amount
of reduced rosGFP2 at equilibrium (R) was measured using a ratio of the
rosGFP2 fluorescence at
510 nm (excitation 490:425 nm). Oxidized rosGFP2 (1 M) was incubated for four
hours in 75 mM
HEPES (pH 7.0), 140 mM NaCl, and 1 mM EDTA, containing varying ratios of
DTTred to DTT0, (1
mM total). The equilibrium constant was determined by fitting the data
according to equation 3.
After nonlinear regression, a Keq of 2.05 x 10"2 was obtained (correlation
coefficient: 0.998).
SEQUENCE LISTING
The nucleic and amino acid sequences listed in the accompanying sequence
listing are
shown using standard letter abbreviations for nucleotide bases, and three
letter code for amino acids,
as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence
is shown, but the
complementary strand is understood as included by any reference to the
displayed strand. In the
accompanying sequence listing:
SEQ ID NO: I shows the amino acid sequence of wild-type GFP.
SEQ ID NO: 2 shows the nucleic acid and amino acid sequence of rosGFP2.
SEQ ID NO: 3 shows the amino acid sequence of rosGFP2.
SEQ ID NO: 4 shows the nucleic acid and amino acid sequence of rosGFPl.
SEQ ID NO: 5 shows the amino acid sequence of rosGFPI.
SEQ ID NO: 6 shows the nucleic acid and amino acid sequence of rosGFP4.
SEQ ID NO: 7 shows the amino acid sequence of rosGFP4.
SEQ ID NO: 8 shows the nucleic acid and amino acid sequence of rosGFP3.
SEQ ID NO: 9 shows the amino acid sequence of rosGFP3.
SEQ ID NO: 10 shows the nucleic acid and amino acid sequence of rosGFP6.
SEQ ID NO: 11 shows the amino acid sequence of rosGFP6.
SEQ ID NO: 12 shows the nucleic acid and amino acid sequence of rosGFP5.
SEQ ID NO: 13 shows the amino acid sequence of rosGFP5.
DETAILED DESCRIPTION
I. Abbreviations
GFP green fluorescent protein
rosGFP redox-sensitive GFP
wtGFP wild-type GFP
IT Terms
Unless otherwise noted, technical terms are used according to conventional
usage.
Definitions of common terms in molecular biology may be found in Benjamin
Lewin, Genes V,
published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et
al. (eds.), The
Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994
(ISBN 0-632-02182-
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
7
9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a
Comprehensive Desk
Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
In order to facilitate review of the various embodiments, the following
explanations of
specific terms are provided:
Animal: Living multi-cellular vertebrate organisms, a category that includes,
for example,
mammals and birds. The term mammal includes both human and non-human mammals.
Similarly,
the term "subject" includes both human and veterinary subjects.
Antibody: A polypeptide substantially encoded by an immunoglobulin gene or
immunoglobulin genes, or fragments thereof, which specifically binds and
recognizes an analyte
(antigen). Immunoglobulin genes include the kappa, lambda, alpha, gamma,
delta, epsilon and mu
constant region genes, as well as the myriad immunoglobulin variable region
genes.
Antibodies exist, e.g., as intact immunoglobulins or as a number of well-
characterized
fragments produced by digestion with various peptidases. For instance, FAbs,
Fvs, and single-chain
Fvs (SCFvs) that bind to GFP would be GFP-specific binding agents. Antibody
fragments are
defined as follows: (1) Fab, the fragment which contains a monovalent antigen-
binding fragment of
an antibody molecule produced by digestion of whole antibody with the enzyme
papain to yield an
intact light chain and a portion of one heavy chain; (2) Fab', the fragment of
an antibody molecule
obtained by treating whole antibody with pepsin, followed by reduction, to
yield an intact light chain
and a portion of the heavy chain; two Fab' fragments are obtained per antibody
molecule; (3) (Fab')2,
the fragment of the antibody obtained by treating whole antibody with the
enzyme pepsin without
subsequent reduction; (4) F(ab')2, a dimer of two Fab' fragments held together
by two disulfide
bonds; (5) Fv, a genetically engineered fragment containing the variable
region of the light chain and
the variable region of the heavy chain expressed as two chains; and (6) single
chain antibody
("SCA"), a genetically engineered molecule containing the variable region of
the light chain, the
variable region of the heavy chain, linked by a suitable polypeptide linker as
a genetically fused
single chain molecule. The term "antibody," as used herein, also includes
antibody fragments either
produced by the modification of whole antibodies or those synthesized de novo
using recombinant
DNA methodologies.
cDNA (complementary DNA): A piece of DNA lacking internal, non-coding segments
(introns) and transcriptional regulatory sequences. cDNA may also contain
untranslated regions
(UTRs) that are responsible for translational control in the corresponding RNA
molecule. cDNA is
usually synthesized in the laboratory by reverse transcription from messenger
RNA extracted from
cells.
Conservative variations: Variants of a particular nucleic acid sequence, which
encode
identical or essentially identical amino acid sequences. Because of the
degeneracy of the genetic
code, a large number of functionally identical nucleic acids encode any given
polypeptide. For
instance, the codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino
acid arginine.
Thus, at every position where an arginine is specified within a protein
encoding sequence, the codon
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
8
can be altered to any of the corresponding codons described without altering
the encoded protein.
Such nucleic acid variations are "silent variations," which are one species of
conservative variations.
Each nucleic acid sequence herein that encodes a polypeptide also describes
every possible silent
variation. The genetic code is shown in Table 1.
Table 1
First position Second position Third position
(S' end) (3' end)
U C A G
Phe Ser Tyr Cys U
U Phe Ser Tyr Cys C
Leu Ser Stop Stop A
Leu Ser Stop Trp G
Leu Pro His Arg U
C Leu Pro His Arg C
Leu Pro GIn Arg A
Leu Pro Gln Arg G
Ile Thr Asn Ser U
A Ile Thr Asn Ser C
Ile Thr Lys Arg A
Met Thr Lys Arg G
Val Ala Asp Gly U
G Val Ala Asp Gly C
Val Ala Glu Gly A
Val Ala Glu Gly G
One of skill will recognize that each codon in a nucleic acid (except AUG,
which is
ordinarily the only codon for methionine) can be modified to yield a
functionally identical molecule
by standard techniques. Accordingly, each "silent variation" of a nucleic acid
that encodes a
polypeptide is implicit in each described sequence.
Furthermore, one of ordinary skill will recognize that individual
substitutions, deletions or
additions which alter, add or delete a single amino acid or a small percentage
of amino acids (for
instance less than 5%, in some embodiments less than 1%) in an encoded
sequence are conservative
variations where the alterations result in the substitution of an amino acid
with a chemically similar
amino acid.
Conservative amino acid substitutions providing functionally similar amino
acids are well
known in the art. The following six groups each contain amino acids that are
conservative
substitutions for one another:
1) Alanine (A), Serine (S), Threonine (T);
2) Aspartic acid (D), Glutamic acid (E);
3) Asparagine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
9
Not all residue positions within a protein will tolerate an otherwise
"conservative" substitution. For
instance, if an amino acid residue is essential for a function of the protein,
even an otherwise
conservative substitution may disrupt that activity. By way of example, in a
GFP the residues that
compose the chromophore do not generally tolerate amino acid substitutions.
Epitope tags: Short stretches of amino acids to which a specific antibody can
be raised,
which in some embodiments allows one to specifically identify and track the
tagged protein that has
been added to a living organism or to cultured cells. Detection of the tagged
molecule can be
achieved using a number of different techniques. Examples of such techniques
include:
immunohistochemistry, immunoprecipitation, flow cytometry, immunofluorescence
microscopy,
ELISA, immunoblotting ("western"), and affinity chromatography. Examples of
useful epitope tags
include FLAG, T7, HA (hemagglutinin) and myc.
Expression control sequence: This phrase refers to nucleotide sequences that
regulate the
expression of a nucleotide sequence to which they are operatively linked.
Expression control
sequences are "operatively linked" to a nucleotide sequence when the
expression control sequences
control and regulate the transcription and, as appropriate, translation of the
nucleotide sequence.
Thus, expression control sequence(s) can include promoters, enhancers,
transcription terminators, a
start codon (i.e., ATG) in front of a protein-encoding sequence, intron
splicing signals, and stop
codons.
Fluorescent property: A characteristic of a fluorescent molecule. Examples of
fluorescent
properties include the molar extinction coefficient at an appropriate
excitation wavelength, the
fluorescence quantum efficiency, the shape of the excitation spectrum or
emission spectrum (the
"fluorescence spectrum", the excitation wavelength maximum and emission
wavelength maximum,
the ratio of excitation amplitudes at two different wavelengths, the ratio of
emission amplitudes at
two different wavelengths, the excited state lifetime, or the fluorescence
anisotropy. A measurable
difference in any one of these properties between wild-type Aequarea GFP and
the mutant form is
useful. A measurable difference can be determined by determining the amount of
any quantitative
fluorescent property, e.g., the amount of fluorescence at a particular
wavelength, or the integral of
fluorescence over the emission spectrum. Determining ratios of excitation
amplitude or emission
amplitude at two different wavelengths ("excitation amplitude ratioing" and
"emission amplitude
ratioing," respectively) for a particular molecule are advantageous. The
ratioing process provides an
internal reference and cancels out variations, for instance in the absolute
brightness of the excitation
source, the sensitivity of the detector, and, light scattering or quenching by
the sample.
Fusion protein: Proteins that have two (or more) parts fused together, which
are not found
joined together in nature. In general, the two domains are genetically fused
together, in that nucleic
acid molecules that encode each protein domain are functionally linked
together, for instance by a
linker oligonucleotide, thereby producing a single fusion-encoding nucleic
acid molecule. The
translated product of such a fusion-encoding nucleic acid molecule is the
fusion protein.
Green fluorescent protein (GFP): GFP is a 238 amino acid, spontaneously
fluorescent
protein, originally isolated from the Pacific Northwest jellyfish Aequorea
victoria. The amino acid
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
sequence of wtGFP is shown in SEQ ID NO: 1. This protein has become an
extremely popular tool
in molecular and cell biology (for reviews: Tsien, Annu. Rev. Biochem. 67:509-
544, 1998;
Remington, In Bioluminescence and chemiluminescence (eds. T.O. Baldwin and
M.M. Sigler), pp.
195-211, 2000, Academic, San Diego, CA.). Originally GFP was used as a passive
indicator of gene
5 expression and protein localization. More recently, GFP has taken on the
role of an active indicator
of such things as intracellular H+, Cat+, and halide ion concentrations (Kneen
et al., Biophys. J.
74:1591-1599, 1998; Llopis et al., Proc. Natl. Acad. Sci. USA 95:6803-6808,
1998; Baird et al., Proc.
Natl. Acad. Sci. USA 96:11241-11246, 1999; Jayaraman et al., J. Biol. Chemn.
275:6047-6050, 2000).
In addition to GFP being highly fluorescent, protease resistant, and very
stable throughout a
10 wide range of pH and solvent conditions, it also has the advantage of being
functional as a single
protein encoded by a single gene. These traits result in a biological probe
molecule that can be
expressed in nearly all organisms. It also can be targeted to subcellular
organelles by a host cell, for
instance through the inclusion of a targeting sequence on the construction
from which it is expressed.
GFP is a non-invasive indicator, which allows for experiments to be conducted
and monitored in a
single cell over a period of time.
GFPs as discussed herein (including rosGFPs) can be expressed as fusion
proteins. The
GFP protein can be functionally fused to, for instance, a tag (such as an
epitope tag), a targeting
molecule (such as a targeting peptide), or a protein (or fragment thereof)
that provides an additional
function, such as a biochemical, biological, or localization function. The
construction and production
of fusion proteins is well known to one of ordinary skill in the art.
A "mutant" GFP is a green fluorescent protein (or nucleic acid encoding such)
that has at
least one residue that is different from (mutated from) the wtGFP. Mutations
include, for instance,
conservative or non-conservative amino acid substitutions, silent mutations
(wherein the nucleic acid
sequence is different from wild-type at a particular residue, but the amino
acid sequence is not),
insertions (including fusion proteins), and deletions. Myriad mutant GFPs are
known, including for
instance those disclosed in the following patent documents: U.S. Patent Nos.
5,804,387; 6,090,919;
6,096,865; 6,054,321; 5,625,048; 5,874,304; 5,777,079; 5,968,750; 6,020,192;
and 6,146,826; and
published international patent application WO 99/64592.
Specific examples of mutant GFPs include proteins in which the fluorescence
spectrum of
the mutant is responsive to an environmental variable, such as temperature,
proton concentration
(pH), salt concentration, and redox status. Particular mutant GFPs as provided
herein are sensitive to
redox status, and others are responsive to both redox status and pH. A
fluorescence spectrum is
"responsive" to an environmental variable if the spectrum changes with changes
in that variable.
Immunoassay: An assay that utilizes an antibody to specifically bind an
analyte. The
immunoassay is characterized by the use of specific binding properties of a
particular antibody to
isolate, target, detect, and/or quantify the analyte, or alternately using a
particularly analyte (e.g., an
antigen) to isolate, target, detect, and/or quantify the antibody.
In vitro amplification: Techniques that increases the number of copies of a
nucleic acid
molecule in a sample or specimen. An example of amplification is the
polymerase chain reaction, in
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
11
which a biological sample collected from a subject is contacted with a pair of
oligonucleotide
primers, under conditions that allow for the hybridization of the primers to
nucleic acid template in
the sample. The primers are extended under suitable conditions, dissociated
from the template, and
then re-annealed, extended, and dissociated to amplify the number of copies of
the nucleic acid. The
product of in vitro amplification may be characterized by electrophoresis,
restriction endonuclease
cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic
acid sequencing, using
standard techniques. Other examples of in vitro amplification techniques
include strand displacement
amplification (see U.S. Patent No. 5,744,311); transcription-free isothermal
amplification (see U.S.
Patent No. 6,033,881); repair chain reaction amplification (see WO 90/01069);
ligase chain reaction
amplification (see EP-A-320 308); gap filling ligase chain reaction
amplification (see U.S. Patent No.
5,427,930); coupled ligase detection and PCR (see U.S. Patent No. 6,027,889);
and NASBATM RNA
transcription-free amplification (see U.S. Patent No. 6,025,134).
Isolated: An "isolated" biological component (such as a nucleic acid molecule,
protein or
organelle) has been substantially separated or purified away from other
biological components in the
cell of the organism in which the component naturally occurs, i.e., other
chromosomal and extra-
chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins
that have been
"isolated" include nucleic acids and proteins purified by standard
purification methods. The term
also embraces nucleic acids and proteins prepared by recombinant expression in
a host cell as well as
chemically synthesized nucleic acids.
Label: A composition detectable by spectroscopic, photochemical, biochemical,
immunochemical, or chemical means. For example, useful labels include 32P (or
other radio-isotope),
fluorescent dyes, fluorescent proteins, electron-dense reagents, enzymes
(e.g., for use in an ELISA),
biotin, dioxigenin, or haptens and proteins or peptides for which antisera or
monoclonal antibodies
are available. A label often generates a measurable signal, such as
radioactivity, fluorescent light or
enzyme activity, which can be used to detect and/or quantitate the amount of
labeled molecule.
Nucleic acid: A deoxyribonucleotide or ribonucleotide polymer in either single-
or double-
stranded form. Unless otherwise limited, this term encompasses known analogs
of natural
nucleotides that can function in a similar manner as naturally occurring
nucleotides. When a nucleic
acid molecule is represented herein by a DNA sequence, the corresponding RNA
molecules are
likewise understood, in which "U" replaces "T."
Oligonucleotide: An oligonucleotide is a plurality of joined nucleotides
joined by native
phosphodiester bonds, between about 6 and about 300 nucleotides in length. An
oligonucleotide analog
refers to moieties that function similarly to oligonucleotides but have non-
naturally occurring portions.
For example, oligonucleotide analogs can contain non-naturally occurring
portions, such as altered
sugar moieties or inter-sugar linkages, such as a phosphorothioate
oligodeoxynucleotide. Functional
analogs of naturally occurring polynucleotides can bind to RNA or DNA, and
include peptide nucleic
acid (PNA) molecules.
Particular oligonucleotides and oligonucleotide analogs can include linear
sequences up to
about 200 nucleotides in length, for example a sequence (such as DNA or RNA)
that is at least 6 bases,
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
12
for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200
bases long, or from about 6 to
about 50 bases, for example about 10-25 bases, such as 12, 15 or 20 bases.
Open reading frame: A series of nucleotide triplets (codons) coding for amino
acids
without any internal termination codons. These sequences are usually
translatable into a peptide.
Operably linked: A first nucleic acid sequence is operably linked with a
second nucleic
acid sequence when the first nucleic acid sequence is placed in a functional
relationship with the
second nucleic acid sequence. For instance, a promoter is operably linked to a
coding sequence if the
promoter affects the transcription or expression of the coding sequence.
Generally, operably linked
DNA sequences are contiguous and, where necessary to join two protein-coding
regions, in the same
reading frame. Similarly, two peptide or polypeptide sequences are considered
to be operably linked
if they are linked to each other in such a way that they function in the
intended manner.
Polypeptide or Protein: A polymer of amino acid residues. The terms apply to
amino acid
polymers in which one or more amino acid residue is an artificial chemical
analogue of a
corresponding naturally occurring amino acid, as well as to naturally
occurring amino acid polymers.
The term "recombinant protein" refers to a protein that is produced by
expression of a nucleotide
sequence (which encodes the protein) from a recombinant DNA molecule.
Preferred mammalian codon(s): The subset of codons from among the set of all
possible
codons encoding an amino acid that are most frequently used in proteins
expressed in mammalian
cells. Table 2 summarizes the preferred mammalian codons for each amino acid:
Table 2
Amino Acid Preferred codons*
Gly GGC, GGG
Glu GAG
Asp GAC
Val GUG, GUC
Ala GCC, GCU
Ser AGC, UCC
Lys AAG
Asn AAC
Met AUG
Ile AUC
Thr ACC
Trp UGG
Cys UGC
Tyr UAU, UAC
Leu CUG
Phe UUC
Arg CGC, AGG, AGA
Gln CAG
His CAC
Pro CCC
Primers: Primers are short nucleic acid molecules, for instance DNA
oligonucleotides 10
nucleotides or more in length. Longer DNA oligonucleotides may be about 15,
20, 25, 30 or 50
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
13
nucleotides or more in length. Primers can be annealed to a complementary
target DNA strand by
nucleic acid hybridization to form a hybrid between the primer and the target
DNA strand, and then the
primer extended along the target DNA strand by a DNA polymerase enzyme. Primer
pairs can be used
for amplification of a nucleic acid sequence, e.g., by the polymerase chain
reaction (PCR) or other
nucleic-acid amplification methods known in the art.
Methods for preparing and using nucleic acid primers are described, for
example, in
Sambrook et al. (In Molecular Cloning: A Laboratory Manual, CSHL, New York,
1989), Ausubel et
al. (ed.) (In Current Protocols in Molecular Biology, John Wiley & Sons, New
York, 1998), and
Innis et al. (PCR Protocols, A Guide to Methods and Applications, Academic
Press, Inc., San Diego,
CA, 1990). Amplification primer pairs can be derived from a known sequence,
for example, by using
computer programs intended for that purpose such as Primer (Version 0.5,O
1991, Whitehead
Institute for Biomedical Research, Cambridge, MA). One of ordinary skill in
the art will appreciate
that the specificity of a particular probe or primer increases with its
length.
Probes: A probe comprises an isolated nucleic acid attached to a detectable
label or
other reporter molecule. Typical labels include radioactive isotopes, enzyme
substrates, co-
factors, ligands, chemiluminescent or fluorescent agents, haptens, and
enzymes. Methods for
labeling and guidance in the choice of labels appropriate for various purposes
are discussed, e.g.,
Sambrook et al. (In Molecular Cloning: A Laboratory Manual, CSHL, New York,
1989) and
Ausubel et al. (In Current Protocols in Molecular Biology, John Wiley & Sons,
New York,
1998).
Promoter: A promoter is an ordered set of nucleic acid control sequences that
direct
transcription of a nucleic acid. A promoter includes necessary nucleic acid
sequences near the start
site of transcription, such as, in the case of a polymerase II type promoter,
a TATA element. A
promoter also optionally includes distal enhancer or repressor elements that
can be located as much
as several thousand base pairs from the start site of transcription.
Purified: The term "purified" does not require absolute purity; rather, it is
intended as a
relative term. Thus, for example, a purified protein preparation is one in
which the protein referred to
is more pure than the protein in its natural environment within a cell or
within a production reaction
chamber (as appropriate).
Recombinant: A recombinant nucleic acid is one that has a sequence that is not
naturally occurring or has a sequence that is made by an artificial
combination of two otherwise
separated segments of sequence. This artificial combination can be
accomplished by chemical
synthesis or, more commonly, by the artificial manipulation of isolated
segments of nucleic
acids, e.g., by genetic engineering techniques.
Recombinant host cell: A cell (such as a bacterial, plant, or animal cell)
that comprises a
recombinant nucleic acid molecule. Thus, for example, recombinant host cells
can express genes
and/or proteins that are not found within the native (non--recombinant) form
of the cell.
Redox status: A measurement of the oxidation-reduction (redox) potential of an
environment, for instance the environment within a cell or a subcellular
compartment.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
14
Fundamentally, redox reactions are a family of reactions that are concerned
with the transfer
of electrons between species. Oxidation represents a loss of electrons,
reduction a gain of electrons.
Oxidation-reduction reactions always occur together, and the electrons gained
by the molecule that is
reduced must balance those given up by the substance that is oxidized. The
oxidation-reduction
potential (or redox status) of a solution is a measurement of the oxidation or
reduction force of the
solution, and is indicative of the oxidation or reduction ability.
Redox status of any solution can be measured. For instance, the redox status
of the solution
within a cell (i.e., the cytosol) can be analyzed using the provided rosGFPs.
Similarly, the redox
status of the solution within a subcellular organelle (such as the nucleus,
mitochondria, plastid,
vacuole, secretory pathway compartment and so forth) can be analyzed.
Stringent conditions: A set of temperature and ionic conditions used in a
nucleic acid
hybridization. Stringent conditions are sequence dependent and are different
under different
environmental parameters. Generally, stringent conditions are selected to be
about 5 C to 20 C
lower than the thermal melting point (T,,,) for the specific target sequence.
The T,,, is the temperature
(under defined ionic strength and pH) at which 50% of the target sequence
hybridizes to a perfectly
matched (100% identical) probe molecule.
Substantially identical/similar: An amino acid sequence or a nucleotide
sequence is
substantially identical (or substantially similar) to a reference sequence if
the amino acid sequence or
nucleotide sequence has at least 80% sequence identity with the reference
sequence over a given
window of comparison. Thus, substantially similar sequences include those
having, for example, at
least 85% sequence identity, at least 90% sequence identity, at least 95%
sequence identity or at least
99% sequence identity. Two sequences that are 100% identical to each other
are, of course, also
substantially identical.
Transformed: A transformed cell is a cell into which has been introduced a
nucleic acid
molecule by molecular biology techniques. As used herein, the term
transformation encompasses all
techniques by which a nucleic acid molecule might be introduced into such a
cell, including
transfection with viral vectors, transformation with plasmid vectors, and
introduction of naked DNA
by electroporation, lipofection, and particle gun acceleration.
Vector: A nucleic acid molecule as introduced into a host cell, thereby
producing a
transformed host cell. A vector may include nucleic acid sequences that permit
it to replicate in a
host cell, such as an origin of replication. A vector may also include one or
more selectable marker
genes and other genetic elements known in the art.
Unless otherwise explained, all technical and scientific terms used herein
have the same
meaning as commonly understood by one of ordinary skill in the art to which
this invention belongs.
The singular terms "a," "an," and "the" include plural referents unless
context clearly indicates
otherwise. Comprises means includes. It is further to be understood that all
base sizes or amino acid
sizes, and all molecular weight or molecular mass values, given for nucleic
acids or polypeptides are
approximate, and are provided for description. Although methods and materials
similar or equivalent
CA 02440592 2010-08-17
86479-1
to those described herein can be used in the practice or testing of the
present invention, suitable
methods and materials are described below. In case of conflict, the present
specification, including
explanations of terms, will control. In addition, the materials, methods and
examples are illustrative only
and not intended to be limiting.
5
III. Redox-Sensitive Green Fluorescent Proteins
Many fundamental biological processes rely upon a properly maintained
intracellular redox
environment (Cuozzo and Kaiser, Nat. Cell Biol. 1:130- 135, 1999; Debarbieux
and Beckwith, Cell
10 99:117-119, 1999; Hall, Eu,. J. Clin. Invest. 29:238-245, 1999; Cai and
Jones, J. Bioenerg. Biomemb.
31:327-334, 1999). Moreover, reactive oxygen species like 0z=-, HO-, or H2O-,,
arise in cells by a
variety of processes including light, radiation, or the respiratory chain.
These radical species present
major threats to organisms by damaging DNA, membranes, or other cellular
components.
The importance of redox status to biological process might imply that
researchers have
15 numerous well-established techniques for monitoring redox potentials in
vivo. However, this is not
the case. Current redox-sensing methods are invasive, require large sample
sizes, are labor intensive,
and do not allow for real-time determinations on living cells.
This disclosure describes a new class of GFP variants (rosGFPs) that display
ratiometric
excitation properties as a function of redox potential. rosGFP biosensors
allow for real-time
measurements of redox status on small groups of cells, individual cells, or
even within certain cellular
organelles. As a result of being genetically encoded, these molecules are non-
invasive, and their
fluorescence characteristics they are easy to use as sensing molecules.
To create a redox sensor that overcomes many of the drawbacks of other methods
of in vivo
redox status determination, site-directed mutagenesis was carried out on the
green fluorescent protein
(GFP). By mutating residues near the chromophore in GFP to cysteines, novel
redox-sensitive GFPs
(rosGFPs) were constructed. They display ratiometric dual-excitation
fluorescent properties as a
function of redox state, with apparent redox potentials of -0.272 to -0.299 V.
Unexpectedly, these rosGFPs also exhibited ratiometric dual-emission
properties in response
to pH changes, providing the unique possibility to simultaneously monitor
redox potential and pH
changes with the same probe. T65S reversion leads to pH-independent redox
sensors with altered
redox potentials and large UV excitation peaks, which can be used to overcome
background levels of
cellular auto-fluorescence.
Crystal structure analyses of an oxidized and reduced rosGFP to 1.9 and 2.0 A,
respectively,
indicate that changes in the structure on reduction or oxidation of the
disulfide bridge could account
for the observed spectral changes.
As shown herein using cultured HeLa cells, rosGFPs can reversibly respond to
exogenous
redox stimuli and have redox potentials near that of mitochondria, with the
apparent redox potential
of mitochondria estimated to more reducing than about -0.30 V. The apparent
redox potential of the
cytosol also was found to be more reducing than -0.30 V.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
16
One example redox sensitive GFP mutant (rosGFP2) differs from wild-type GFP in
that it
contains the following amino acid residue mutations:
C48S/S65T/Q80R/S147C/Q204C (SEQ ID
NOs: 2 and 3). Figure 1 illustrates how the fluorescence of rosGFP2 varies in
response to changes in
redox potential. The spectra show two excitation peaks, one near 400 nm and
the other at about 490
nm, with a clear isosbestic point separating them. These dual excitation peaks
respond in opposite
directions to redox potential, making this indicator ratiometric for redox
potential. Ratiometric
indicators are known to reduce or eliminate distortions of data caused by
photobleaching, indicator
concentration, variable cell thickness, illumination stability, excitation
pathlength, and non-uniform
indicator distribution within cells or between groups of cells (Grynkiewicz et
al., J. Biol. Chein.
260:3440-3450, 1985).
By monitoring the chromophore fluorescence at the 490 nm excitation peak as a
function of
redox potential, the apparent redox potential of rosGFP2 was found. Figure 2
shows the titration of
rosGFP2 with dithiothreitol. From this plot the apparent redox potential is -
0.279 volts. To
demonstrate that the redox-sensitive probe responds to in vivo redox changes,
it was targeted to the
mitochondria of HeLa cells. As seen in Figure 3, the starting ratio of the 400
to 490 nm peak in
mitochondria is around 0.28. After the addition of the redox-cycling agent
vitamin K3, the ratio
dramatically increases to about 0.42. This increase in the ratio is indicative
of an oxidation event that
is to be expected according to the reaction catalyzed by vitamin K3 (Suttie,
Annu. Rev. Biochem.
54:459-477, 1985). After 30 total minutes, the addition of dithiothreitol
elicits the opposite response
as indicated by the smaller ratio.
Characteristics of several redox-sensitive GFP mutants are summarized in Table
3.
Table 3
Mutant Excitation Redox
name Substitutions Peaks Potential*
rosGFP2 C48S/S65T/S147C/Q204C 400 nm -0.272
(SEQ ID NOs: 2 and 3) 490 nm
rosGFPl C48S/S147C/Q204C 397 nm -0.288
(SEQ ID NOs: 4 and 5) 477 nm
rosGFP4 C48S/S65T/N149C/S202C 400 nm -0.286
(SEQ ID NOs: 6 and 7) 490 urn
rosGFP3 C48S/N149C/S202C 392 nm -0.299
(SEQ ID NOs: 8and 9) 475 mn
rosGFP6 C48S/S65T/S 147C/N149C/S202C/Q204C 398 nm -0.280
(SEQ ID NOs: 10 and 11) 490 urn
rosGFP5 C48S/S147C/N149C/S202C/Q204C 395 nm -0.296
(SEQ ID NOs: 12 and 13) 475 nm
volts
Properties of rosGFPs
Examples of redox-sensitive GFPs described herein have many desirable
qualities. In
addition to being genetically encoded fluorescent indicators, they are
ratiometric. This ratiometric
behavior has the advantage of reducing or eliminating distortions of data
caused by photobleaching,
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
17
indicator concentration, variable cell thickness, illumination stability,
excitation path length, and non-
uniform indicator distribution within cells or between groups of cells
(Grynkiewicz et al., J. Biol.
Chem. 260:3440-3448, 1985; Whitaker et al., Anal. Biochem. 194:330-344, 1991).
In addition, a
ratio of excitation wavelengths greatly minimizes the contribution of pH
artifacts to the fluorescent
signal over a pH range from 6 to 8.5. Similarly, a ratio of emission
wavelengths can result in pH
monitoring without artifacts introduced by the redox state of the biosensor.
The second-generation rosGFPs, with more closely matched excitation peak
amplitudes,
may aid in fluorescence microscopy experiments by allowing the same
camera/detector settings to
capture both images that constitute the ratio. Furthermore, second-generation
rosGFPs have a larger
400 nm fluorescence amplitude, which is desirable for detection of the rosGFP
probe over
background levels of cellular autofluorescence.
Accuracy of Standard Redox Potentials
The main problem in the determination of redox potentials is that E,, values
cannot be
measured directly, but rather are calculated from the known E,, of another
redox couple, equilibrated
with the redox couple of unknown E0. The standard redox potential can thus
vary over a large range
depending on experimental conditions and the choice of redox couple.
In this disclosure, the value of -0.323 V for the dithiothreitol couple was
chosen, because it
has been very accurately determined in 0.05-0.02 M phosphate buffer at pH 7.0
and 30.0 +/- 0.5 C
using the lipoamide-lipoamide dehydrogenase couple (Szajewski and Whitesides,
J. Am. Chem. Soc.
102:2011-2026, 1980). Because redox potentials are pH and temperature
dependant, all redox
equilibria were measured at the same pH (7.0) and temperature (30 C) as was
used to evaluate the
standard redox potential of the dithiothreitol couple. Another reason to use
the value of -0.323 V for
the dithiothreitol couple is that the standard potentials of other commonly
used thiol reagents
(including the GSH-GSSG couple) have been determined under identical
conditions (Szajewski and
Whitesides, J. Am. Chem. Soc. 102:2011-2026, 1980). This will allow for the
direct comparison of
redox potentials determined by use of rosGFPs to those determined by other
methods, provided the
experimental conditions are reproduced.
For the DTTred-DTT0x couple, the standard potential throughout literature is
well accepted to
be about -0.330 V at near biochemist's standard state of pH 7 and 25 'C.
However, such agreement
is not always the norm. In the case of the glutathione redox couple, very
different values for the
standard redox potential have been reported. The published values deviate from
a somewhat
oxidizing value of -0.205 V to a more reducing value of -0.250 V (Szajewski
and Whitesides, J. Am.
Chem. Soc. 102:2011-2026, 1980; Rost and Rapoport, Nature 201:185, 1964;
Torchinsky, Sulfur in
proteins. Pergamon Press Ltd., 1981, New York, NY). The 45 mV difference in
literature values
might be problematic when trying to compare redox potentials of rosGFPs to
previously determined
estimates of the redox potential inside cells.
Even with the large discrepancy in the standard potential of GSH-GSSG, results
reported
herein indicate that in vivo redox potentials may be more reducing than
previous estimates. Hwang et
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
18
al., using the tetrapeptide N-Acetyl-Asn-Tyr-Thr-Cys-NH2 to measure the ratio
of thiol to disulfide in
the cytosol and secretory pathway of cultured cells, concluded that the
cytosol is more reducing than
the secretory pathway with an approximate redox potential of-0.221 to -0.236 V
versus -0.170 to -
0.185 V, respectively (Hwang et al., Science 257:1496-1502, 1992). In
addition, based on prior
determinations of the concentration and ratio of GSH to GSSG in mitochondria,
the redox potential of
this compartment is calculated to be -0.210 to -0.230 V. However, Keese et al.
recently developed
an indicator of redox state in which they transfer glutathione reductase
crystals into the cytosol of
living cells and then detect a color change in the crystals (Keese et al.,
FEBS Lett. 447:135-138,
1999). Using that method, Keese et al. determined the redox potential of the
cytosol of human
fibroblasts to be more reducing than -0.270 V at pH 7.4 and 37 C. That result
is in agreement with
the estimate reported herein of the cytosolic redox potential for HeLa cells
being more negative than
-0.330 V.
IV. Construction of rosGFPs
The examples below provide specific methods for producing certain embodiment
rosGFPs.
More generally, in light of the disclosure herein that disulfide bonding pairs
can be incorporated into
GFP to produce redox-sensitive GFP mutants, it will be understood to one of
ordinary skill in the art
that many different methods could be used to make rosGFPs.
A. GFP nucleic acids and site-directed mutations
DNA encoding wtGFP is available commercially, for example from CLONTECH (Palo
Alto, CA). Methods of producing mutants containing a predetermined nucleotide
sequence are well
known to those of ordinary skill in the art. Two widely used methods are
Kunkel mutagenesis and
PCR mutagenesis. A detailed description of the two techniques can be found in
Current Protocols in
Molecular Biology, Wiley Interscience, 1987, Sections 8.1 and 8.5
respectively. See also Kunkel,
Proc. Acad. Nat. Sci. USA 82:488-492, 1985; and Saiki et al., Science 239:487-
491, 1988.
It is also possible to synthesize mutant GFPs and DNA encoding for mutant GFPs
directly,
by synthetic methods well known in the art. The mutant sequences can be
expressed in a variety of
systems, including bacterial, yeast, plant and mammalian cells. DNA encoding
the mutant GFP is
inserted in an expression vector and transformed into cells of interest. The
sequence encoding for
GFP is inserted in the vector in the correct reading frame near a strong
promoter, and the expression
of GFP is induced. Vectors suitable for specific expression systems are well
known in the art, and are
widely available commercially. Vectors having codons optimized for expression
in a variety of
systems, including yeast and mammalian cells, are also available. For a
description of silent
nucleotide sequence mutations optimized for mammalian expression, see for
example Haas et al.
(Curr. Biol. 6:315-324, 1996).
B. Expression of rosGFPs
One skilled in the art will understand that there are myriad ways to express a
recombinant
protein such that it can subsequently be purified. In general, an expression
vector carrying the
nucleic acid sequence that encodes the desired protein will be transformed
into a microorganism for
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
19
expression. Such microorganisms can be prokaryotic (bacteria) or eukaryotic
(e.g., yeast). One
appropriate species of bacteria is Escherichia coli (E. coli), which has been
used extensively as a
laboratory experimental expression system. A eukaryotic expression system will
be preferred where
the protein of interest (or a domain within a fusion protein of interest)
requires eukaryote-specific
post-translational modifications such as glycosylation. Also, protein can be
expressed using a viral
(e.g., vaccinia) based expression system. Protein can also be expressed in
animal cell tissue culture,
and such a system will be appropriate where animal-specific protein
modifications are desirable or
required in the recombinant protein.
The expression vector can include a sequence encoding a targeting peptide,
positioned in
such a way as to be fused to the coding sequence of the rosGFP. Targeting
domains may allow the
fusion protein to be targeted to specific extra-cellular locations, or simply
to be secreted from the cell,
and may be removed during or soon after synthesis of the fusion protein. In
addition, multiple
targeting peptides can be included in a single fusion, for instance a
peptide/domain that directs the
fusion protein to be secreted, and another peptide/domain that directs the
secreted protein to a target
(cell, tissue, organ, etc.). Various appropriate prokaryotic and eukaryotic
targeting peptides, and
nucleic acid molecules encoding such, are known to one of ordinary skill in
the art. Through the use
of a eukaryotic secretion-type signal sequence, a rosGFP fusion protein can be
expressed in a
transgenic animal (for instance a cow, pig, or sheep) in such a manner that
the fusion protein is
secreted into the milk of the animal. Targeting protein portions also may be
used to ensure that a
transgenically expressed fusion protein is secreted into the circulatory
system of the transgenic
animal, thereby permitting the fusion protein to be transported to a target
(cell, tissue, organ, etc.).
Optional localization peptide sequences may be, for instance, a nuclear
localization
sequence, an endoplasmic reticulum localization sequence, a peroxisome
localization sequence, a
mitochondrial localization sequence, or a localized protein. Localization
sequences can be targeting
sequences which are described, for example, in "Protein Targeting," chapter 35
of Stryer,
Biochemistry (4th ed.). W. H. Freeman, 1995. The localization sequence can
also be a localized
protein (or domain thereof). Some localization sequences include the following
non-limiting
examples (Table 4):
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
Table 4
Subcellular location Localization sequence(s)
nucleus KKKRK
mitochondrion MLRTSSLFTRRVQPSLFRNILRLQST-
endoplasmic reticulum KDEL (providing retention in the ER)
when used with a signal sequence*
peroxisome SKF
prenylation or insertion into plasma CaaX, CC, CXC, or CCXX
membrane
cytoplasmic side of plasma membrane fusion to SNAP-25
Golgi fusion to furin
*amino terminal
**carboxy terminal
5 Vectors suitable for stable transformation of culturable cells are also well
known.
Typically, such vectors include a multiple-cloning site suitable for inserting
a cloned nucleic acid
molecule, such that it will be under the transcriptional control of 5' and 3'
regulatory sequences. In
addition, transformation vectors include one or more selectable markers; for
bacterial transformation
this is often an antibiotic resistance gene. Such transformation vectors
typically also contain a
10 promoter regulatory region (e.g., a regulatory region controlling inducible
or constitutive
expression), a transcription initiation start site, a ribosome binding site,
an RNA processing signal,
and a transcription termination site, each functionally arranged in relation
to the multiple-cloning
site. For production of large amounts of recombinant proteins, an inducible
promoter is preferred.
This permits selective production of the recombinant protein, and allows both
higher levels of
15 production than constitutive promoters, and enables the production of
recombinant proteins that may
be toxic to the expressing cell if expressed constitutively.
In addition to these general guidelines, protein expression/purification kits
are produced
commercially. See, for instance, the QIAexpressTM expression system from
QIAGEN (Chatsworth,
CA) and various expression systems provided by INVITROGEN (Carlsbad, CA).
20 C. Purification ofrosGFPs
One skilled in the art will understand that there are myriad ways to purify
recombinant
polypeptides, and such typical methods of protein purification may be used to
purify the disclosed
rosGFPs. Such methods include, for instance, protein chromatographic methods
including ion
exchange, gel filtration, HPLC, monoclonal antibody affinity chromatography
and isolation of
insoluble protein inclusion bodies after over production. In addition,
purification affinity-tags, for
instance a six-histidine sequence, may be recombinantly fused to the protein
and used to facilitate
polypeptide purification (e.g., in addition to another functionalizing portion
of the fusion, such as a
targeting domain or another tag). A specific proteolytic site, for instance a
thrombin-specific
digestion site, can be engineered into the protein between the tag and the
remainder of the fusion to
facilitate removal of the tag after purification, if such removal is desired.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
21
Commercially produced protein expression/purification kits provide tailored
protocols for
the purification of proteins made using each system. See, for instance, the
QlAexpressTM expression
system from QIAGEN (Chatsworth, CA) and various expression systems provided by
INVITROGEN
(Carlsbad, CA). Where a commercial kit is employed to produce a rosGFP, the
manufacturer's
purification protocol is a preferred protocol for purification of that
protein. For instance, proteins
expressed with an amino-terminal hexa-histidine tag can be purified by binding
to nickel-
nitrilotriacetic acid (Ni-NTA) metal affinity chromatography matrix (The
QIAexpressionist,
QIAGEN, 1997).
D. Optional Modifications to rosGFPs
Optionally, redox-sensitive GFP variants/mutants can be "humanized" as
described in U.S.
Patent No. 5,874,304, or can contain other mutations (such as substitutions)
as dictated by the end-
use of the protein.
Also, the mutant GFP proteins can be expressed as part of a fusion protein.
The construction
of fusion proteins from domains of known proteins, or from whole proteins or
proteins and peptides,
is well known. In general, a nucleic acid molecule that encodes the desired
protein and/or peptide
portions are joined using genetic engineering techniques to create a single,
operably linked fusion
oligonucleotide. Appropriate molecular biological techniques may be found in
Sambrook et al.
(1989). Examples of genetically engineered multi-domain proteins, including
those joined by various
linkers, and those containing peptide tags, can be found in the following
patent documents:
U.S. Patent No. 5,994,104 ("Interleukin-12 fusion protein");
U.S. Patent No. 5,981,177 ("Protein fusion method and construction");
U.S. Patent No. 5,914,254 ("Expression of fusion polypeptides transported out
of the
cytoplasm without leader sequences");
U.S. Patent No. 5,856,456 ("Linker for linked fusion polypeptides");
U.S. Patent No. 5,767,260 ("Antigen-binding fusion proteins");
U.S. Patent No. 5,696,237 ("Recombinant antibody-toxin fusion protein");
U.S. Patent No. 5,587,455 ("Cytotoxic agent against specific virus
infection");
U.S. Patent No. 4,851,341 ("Immunoaffmity purification system");
U.S. Patent No. 4,703,004 ("Synthesis of protein with an identification
peptide"); and
WO 98/36087 ("Immunological tolerance to HIV epitopes").
In particular, patent disclosures related to fusion proteins containing a GFP
moiety include the
following:
U.S. Patent No. 6,180,343 ("Green fluorescent protein fusions with random
peptides");
WO 99/54348 ("Rapidly degrading GFP-fusion proteins and methods of use");
WO 99/19470 ("GFP-annexin fusion proteins")
WO 98/14605 ("Renilla luciferase and green fluorescent protein fusion genes");
and
EP 949269 ("Biosensor protein").
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
22
V. Applications
With the provision of redox-sensitive GFP indicators, methods of monitoring
redox changes
in real time in a targeted environment, for instance in the mitochondria (or
other subcellular
compartment) of single living cells, are enabled.
Redox-sensitive GFPs mutant are useful in a wide variety of applications,
including the
monitoring of redox status of individual cells or subcellular compartments.
Certain of the provided
rosGFPs are also useful for monitoring pH concurrently with redox status, as
explained herein.
Mutant GFPs as described herein are suitable for use as markers for
transformation of
mammalian cells. Often, a gene of therapeutic interest does not produce an
easily distinguishable
phenotype in cells expressing that gene. Thus, such a therapeutic gene can be
inserted into a vector
that contains a marker gene. The therapeutic gene and the marker gene are
placed in the vector under
the control of a cellular or viral promoter, and introduced into mammalian
cells of interest;
subsequently, the transfected cells (the cells containing the vector) are
selected according to the
phenotype determined by the marker gene. The use of GFP for selection obviates
the need to grow
the mammalian cells of interest in the presence of drugs in order to select
for the transfected cells. In
addition, due to the redox-sensitive nature of the provided GFP mutants, the
redox status of the
transformed cells (or respective subcellular compartment(s)) can be directly
measured. Cells
transformed with a nucleic acid comprising a rosGFP can be sorted by FACS.
For the study of protein localization, fusion of a rosGFP mutant and a
sequence encoding a
cellular protein (or encoding a fragment, sub-domain, or domain of a protein),
and subsequent
expression of the fusion construct, results in a fluorescent fusion protein
that is localized at the
normal intracellular location of the protein encoded by the nucleic acid
sequence of interest.
Identifying the intracellular location of the mutant GFP thus identifies the
intracellular location of the
protein of interest. The use of such fusion proteins yields information on the
normal cellular role of
the protein encoded by the gene of interest, and provides direct measurement
of the redox status (and
in some embodiments, pH) of the intracellular environment to which it was
targeted. Such an
application using wtGFP is described in more detail, for example, in an
article by Olson at al. (J. Cell
Biol., 130:639-650,1995).
Also provided are rosGFPs that are sensitive to pH, including for instance
rosGFP2, 4, and
6. Dual sensor GFPs such as these can be used in any situation in which it is
beneficial to monitor or
measure both pH and redox status in an environment.
VI. Kits
Kits are provided that contain at least one rosGFP protein, or a nucleic acid
molecule (e.g., a
vector) that encodes such a protein, or both, in one or more contains. The
provided kits may also
include written instructions. The instructions can provide calibration curves
or charts to compare
with the determined (e.g., experimentally measured) values. Included are kits
that can be used for
diagnosis or prognosis of a disease or other condition associated with a
change in the redox status of
cell or sub-cellular compartment.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
23
The invention is illustrated by the following non-limiting Examples.
EXAMPLES
Example 1: Selection and Design of Redox-Sensitive GFPs
In order to create redox-sensitive GFPs, two cysteine residues were introduced
into GFP that
would be within disulfide bonding distance of each other, near the
chromophore, and on the surface
of the protein. The cysteine residues bring about fluorescence changes based
upon whether they are
reduced or oxidized. In addition, by being on the surface of the protein, the
cysteines are solvent
accessible, which enables them to reversibly respond to redox changes in the
surrounding
environment.
After close examination of the crystal structure of the S65T variant of GFP,
two borderline
suitable sites for the introduction of a pair of cysteines were chosen. The
first site chosen was
positions 147 and 204, while the second site chosen was positions 149 and 202.
All four amino acid
side-chains at these positions pointed away from the protein's interior. The
distance between the Cq
Ca and Cp-Cp positions for site one were 4.6 A each, and for site two the
distance between these
positions were 4.8 and 5.9 A, respectively. These distances did not agree with
previous reports on
ideal geometry for the introduction of disulfide bridges in proteins. In
addition, neither of these site
pairs were chosen by a disulfide bridge modeling program (Sowdhamini et al.,
Protein Eng. 3:95-
103, 1989). There were, however, some indications that one or both of these
pairs of cysteines might
be able to form a disulfide bond. Such evidence came from the irregular
"bulging" nature of the (3-
strand encompassing positions 147 and 149, which has previously been shown to
move in response to
substitution at position 148 (Wachter et al., Structure 6:1267-1277, 1998).
Flexibility has been
suggested to help ensure that a protein can both adjust to the perturbation
due to replacements with
cysteine residues as well as to allow the disulfide bridge to assume near-
optimal geometry
(Matsumura et al., Proc. Natl. Acad. Sci. USA 86:6562-6566, 1989). The 147/204
and 149/202 sites
best fit the criteria.
Example 2: Construction and Expression of Redox Sensitive GFPs
Wild-type GFP contains two cysteine residues at positions 48 and 70. To avoid
possible
thiol/disulfide interchange reactions with the newly engineered cysteines,
cysteine 48 and cysteine 70
were replaced with serine and alanine, respectively. Although the substitution
C48S did not alter the
properties of GFP, C70A appeared to be deleterious to obtaining soluble,
fluorescent protein. Since
position 70 is located within the interior of GFP and is in close proximity to
the chromophore, it was
deemed a mutation-sensitive position and was therefore left as a cysteine.
The C48S mutation was introduced into a histidine-tagged version of the S65T
variant of
GFP in the plasmid pRSETB. This construct served as the template for
introduction of the cysteines
at sites one (S147C/Q204C) and two (N149C/S202C). All mutations were
introduced via the
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
24
QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA),
following the
manufacturer's protocol. Mutations were verified by DNA sequencing of the
entire GFP coding
sequence.
Mutant protein was recombinantly expressed in Escherichia coli, strain
JM109(DE3).
Transformed bacteria were grown in four liters of S-LBH media at 37 C,
stirred at 450 rpm, with 5
liters per minute air flow, and in the presence of 0.27 mM ampicillin. After
the culture reached a
density of approximately OD595 equal to 0.8, then protein expression was
induced by addition of
isopropyl-(3-D thiogalactopyranoside (IPTG) to a final concentration of 1 mM.
At the same time the
temperature of the culture was reduced to 16 C and the culture allowed to
grow for an addition 16
hours. Cells were then harvested by centrifugation at 4 C in a Beckman KA-
9.1000 rotor at 11,800 x
g for 10 minutes.
The bacterial cell pellet was resuspended in 100 mL of 50 mM HEPES (pH 7.9),
300 mM
NaCl, 10% glycerol, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). The
resuspended cells
were sonicated for a total of five minutes, and the lysate clarified twice by
centrifugation at 35,000 x
g in a Beckman JA-20 rotor at 4 C for 20 minutes.
The resultant supernatant was loaded onto a pre-equilibrated nickel-
nitrilotriacetic acid (Ni-
NTA) metal-affinity column (Qiagen, Hilden, Germany). The equilibration and
subsequent washing
of the column was performed with washing buffer (50 mM HEPES (pH 7.9) and 300
mM NaCl).
Proteins were eluted from the column by a step gradient of (1) washing buffer
plus 20 mM imidazole
to remove mostly unwanted proteins, and then (2) washing buffer plus 100 mM
imidazole to elute the
mutant GFP. To remove the amino-terminal histidine tag and as a further
purification step the eluted
protein was incubated with'/50 w/w y-chymotrypsin at 22 C for 22 hours. The
protein preparation
was finally buffer exchanged on a Sephadex G-25 column. Characteristic yields
of mutant GFP
protein were in the range of 15 to 100 milligrams and with a purity greater
than 95%.
Example 3: Disulfide-Bond Formation and Redox Sensitivity of rosGFPs
Samples of rosGFP2 and GFP S65T (control) were treated with 1 mM DTT or 1 M
CuC12
and incubated at room temperature for 3-4 hours, then 2 mM N-ethyl maleimide
was added to prevent
disulfide exchange reactions. Molecular weights were determined by comparison
to BenchMarkTM
protein ladder (InVitrogen, Carlsbad, CA). The gel was visualized with
Coomassie blue stain.
Results
To verify that the introduced cysteines formed disulfide bonds and to show
that the disulfide
bonds were intramolecular, SDS-PAGE was run on redox-sensitive GFP #2
(rosGFP2), harboring the
mutations C48S/S65T/S147C/Q204C, and on a control GFP (C48S/S65T) under
reducing and non-
reducing conditions. If an intramolecular disulfide bond forms, the resulting
polypeptide would be
expected to migrate further based on its slightly more compact structure in
the denatured form.
However, if an intermolecular disulfide bridge forms, then a large molecular
weight band (-60 kDa)
corresponding to a disulfide-linked dimer, would be expected.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
The results (Figure 4) indicate that the introduced cysteines form
intramolecular disulfide
cross-links, but are unable to produce disulfide-linked dimers. This can be
seen by comparing lanes
11 and 12 with lanes 14-16 or lanes 21 and 22 with lanes 17-19 (Figure 4).
5 Example 4: Determination of Redox Potentials
Apparent redox potential values for the rosGFPs were found by exploiting the
fact that the
fluorescence of the rosGFP chromophores is strongly dependent upon the redox
state of the
introduced cysteines. Therefore the redox equilibrium of the rosGFPs with
dithiothreitol (DTTred)
and oxidized dithiothreitol (DTTox) was analyzed. The equilibrium for the
oxidation of reduced
10 rosGFP by DTTred and its equilibrium constant (Keq) are given by equations
1 and 2.
rosGFPred + DTTox H rosGFPox + DTTred (1)
Keq = [rosGFPox] [DTTred] / [rosGFPred] [DTTox] (2)
When rosGFPs were incubated in the presence of varying concentrations of
DTT7ed and DTTox (total
15 DTTred + DTTox = 1 mM), the fractional amount of reduced rosGFP at
equilibrium (R) could be
measured over the whole range from the oxidized to the reduced protein using
the chromophore
fluorescence (Figure 20). Based on the SDS-PAGE result that indicated rosGFPs
only form
intramolecular disulfide bonds, R can be related to Keq by equation 3 (Hawkins
et al., Biochein J 1991
275(2):341-348).
R = ([DTTred] / [DTTox]) / (Keq + [DTTred] / [DTTox]) (3)
For experimental determination of the equilibrium constants of the
GFP:dithiothreitol system, the
equilibrium concentrations of DTTred and DTTox were calculated according to
equations 4-6, where
[DTTred o] and [DTTox o] are the initial concentrations of DTT7ed and DTTox,
respectively, R is the
fractional amount of reduced rosGFP at equilibrium, [rosGFPo] is the initial
concentration of oxidized
rosGFP, F is a fluorescence intensity ratio of band B excitation (490 nm)
versus the isosbestic point
(425 nm), and Fox and Fred are the 490:425 nm ratios of the completely
oxidized and reduced protein,
respectively. By plotting R against the
[DTTred] = [DTTred o] - R [rosGFPo] (4)
[DTTox] _ [DTTox o] + R [rosGFPo] (5)
R = (F - Fax) / (Fred - Fox) (6)
[DTTred]/[DTTox] ratio and fitting the data to a titration curve according to
equation 3 (Figure 21), the
Keq for the rosGFP I: dithiothreitol system was found to be 2.05 x 10"2. The
redox potential of
rosGFP2 at pH 7 and 30 C (Eo'rosGFP2) was then calculated from the Nernst
equation (7), where Eo' is
the biochemist's standard potential of the DTT/DTTox couple (Eo DTT = -0.323
V, at pH 7 and 30 C;
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
26
Szajewski and Whitesides 1980), R is the gas constant (8.315 J K"' moF'), T is
the absolute
temperature (303.15 K), n is the number of transferred electrons (2), and F is
the Faraday constant
(9.649 x 104 C mol"') and found to be -0.272 V.
Eo rosGFP2 = Eo DTT - (RT / nF) x In KeQ (7)
Redox potentials involving the liberation of H+ ions are intrinsically based
on pH. The pH-
dependence on the redox potential is more apparent when examining the two half-
reactions involving
rosGFP and DTT (equation 8 and 9).
rosGFP0X + 2H+ + 2e" H rosGFPred (8)
DTTLed <-> DTTQX + 2H+ + 2e" (9)
At equilibrium the concentrations of rosGFPox and rosGFPred are equal and thus
the Keq is equal to the
[H+]2. The standard redox potential of rosGFP2 (Eo rosGFP2) at pH 0 could then
be determined from
equation 10.
Eo rosGFP2 = Eo'rosGFP2 - (RT / nF) x In Keq (10)
Eo rosGFP2 was calculated to be 0.149 V. Equation 11 simplifies the expression
for the pH-dependence
of redox potentials involving two protons.
E0H=Ea'-60.2mVx(pH-7) (11)
The pH-dependence on the redox potential therefore changes 60.2 mV with each
pH unit.
Experimentally Eo rosGFP2 varied 65.5 mV per pH unit from pH 6 to 8
(correlation coefficient: 0.9999).
Therefore, although a linear correlation between pH and Eo rosGFP2 is
observed, the pH-dependence of
the rosGFP2 standard potential does not directly correspond to this model. The
deviation from this
model for the pH-dependence of Eo may be due in part to the contributions of
charged residues near
the introduced disulfide of rosGFP2 as well as potentially different pKa
values for the cysteine
residues (Wunderlich and Glockshuber, Protein Sci 2(5):717-726, 1993;
Wunderlich and
Glockshuber, JBiol Chem 268(33):24547-24550, 1993)
Example 5: Spectral Analysis of rosGFPs
Spectroscopy and pH Titrations
Absorbance measurements were performed on a Shimadzu 2101 spectrophotometer.
The
molar extinction coefficient of GFP S65T (X280 a,,, = 19,890 M"' cm-1) was
calculated from its amino
acid sequence as previously described (Gill and von Hippel, Anal. Biochem.
182:319-326, 1989), and
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
27
used to determine protein concentrations of the rosGFPs. pH titrations were
performed using
approximately 200 gg mL-1 mutant GFP in 75 mM buffer, 140 mM NaCl and either 1
M CuC12 or 5
mM DTT. According to the desired pH, an appropriate buffer was chosen from
MES, HEPES, or
CHES and the final pH was adjusted by addition of HCl or NaOH. The absorbance
was then scanned
between 250 and 550 nm and the optical density of the long-wave band B was
plotted as a function of
pH and fitted to a titration curve to obtain pKa values.
Fluorescence excitation spectra at various pHs were attained on a Hitachi
F4500
fluorescence spectrophotometer or a Perkin Elmer LS 55 luminescence
spectrometer at protein
concentrations of approximately 100 g mL"' in the same buffers used for
absorbance measurements.
Apparent chromophore pKa values were determined by plotting the emission
intensity when excited
at band B as a function of pH and fitting the data to a titration curve
(KaleidagraphTM). In all cases,
the pKa values determined by absorbance and fluorescence differed by no more
than +/- 0.05 of a pH
unit. All plots and curve fits were made with KaleidagraphTM (Abelbeck
Software).
Redox Titrations
Fluorescence measurements were performed at 30 C using a themostated cuvette
holder.
Samples consisted of I gM GFP in 75 mM HEPES (pH 7.0), 140 mM NaCI, 1 mM EDTA,
and 1 mM
total DTT (mixture of oxidized and reduced forms). To exclude air oxidation,
the solutions were
degassed and subsequently flushed with nitrogen. In general equilibration was
reached within one
hour at pH 7Ø Equilibration of rosGFPs was ensured by incubating the samples
at 30 C for four
hours. The reaction appeared to be at equilibrium, since the ratio of oxidized
and reduced protein, as
determined by fluorescence, did not change between 4 and 16 hour incubation
times.
Spectral Characteristics
To test whether the introduced cysteines affect the spectral properties of
GFP, absorbance
and fluorescence scans were collected at varying redox potentials. To
establish various redox
potentials, GFP was equilibrated with varying concentrations of dithiothreitol
(DTT) and oxidized
DTT (DTTOX). Figure 5 shows the absorbance and fluorescence excitation spectra
of rosGFP2 as a
function of redox potential. With a disulfide bond formed under oxidizing
conditions, the 400 nm
peak (band A) was maximized whereas the 490 nm peak (band B) was minimized.
Conversely, in the
absence of a disulfide cross-link achieved with reducing conditions, band B
was at a maximum, while
band A was at a minimum. The two peaks were separated by a clean isosbestic
point at 425 nm,
indicative of two species interconverting. The redox potential of rosGFP2 was
then determined from
the equilibrium constant obtained by plotting the fraction of reduced protein
versus the ratio of
DTTred to DTTOX (see Example 4) and discovered to be -0.272 V.
Introducing a pair of cysteines at the alternative site also yielded a mutant
protein whose
fluorescent properties varied in response to redox potential (Figure 6A). The
rosGFP4 variant,
having the mutations C48S/S65T/N149C/S202C, displayed increased band B
fluorescence over
rosGFP2, however band A fluorescence intensity was almost non-existent. The
fluorescence
isosbestic point of rosGFP4 was shifted to approximately 400 nm (Figure 6B).
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
28
Combining the two pairs of cysteine substitutions resulted in a variant
(C48S/S65T/S147C/N149C/S202C/Q204C, rosGFP6), whose properties appeared to be
an average of
both rosGFP2 and rosGFP4. Figure 7 shows the fluorescence excitation spectra
of rosGFP6. In this
variant the dynamic range of the two excitation peaks as well as the
isosbestic point lie in the middle
of the values observed for either rosGFP2 or rosGFP4.
The overall dynamic range of the excitation ratio (S), determined by dividing
the maximum
and minimum possible excitation peak ratios, was found to be 5.4 for rosGFP6.
Table 5 summarizes
the spectroscopic and biochemical parameters of the rosGFP variants.
Table 5. Spectroscopic and Biochemical Properties of rosGFPs.
Name Mutations' &12 Eo' (V)' 15,
rosGFP2 S65T/S147C/Q204C 0.0205 -0.272 5.8
rosGFPl S147C/Q204C 0.0702 -0.288 6.1
rosGFP4 S65T/N149C/S202C 0.0561 -0.286 2.6
rosGFP3 N149C/S202C 0.1505 -0.299 4.3
rosGFP6 S65T/S 147C/N149C/S202C/Q204C 0.0385 -0.280 5.4
rosGFP5 S147C/N149C/S202C/Q204C 0.1341 -0.296 7.8
'All variants contain the phenotypically neutral C48S and Q80R substitutions.
3Equilibrium constant (Keq) values refer to equilibration of rosGFPs with the
DTTred/DTT0x
couple.
3Redox potentials (E0') were calculated at pH 7 and 30 C using the Keq for the
GFP-
dithiothreitol system (see Appendix).
46 is the maximum excitation peak ratio change in number of fold.
pH-Sensitivity of rosGFPs
Previous work has shown that, while the fluorescence of wild-type GFP is
unaffected
throughout the biologically relevant pH range from 6 to 8 (Ward and Bokman,
Photochem.
Photobiol. 35:803-808, 1982), GFP variants harboring the S65T mutation often
exhibit dramatic
fluorescence changes over this pH range (Kneen et al., Biophys. J 74:1591-
1599, 1998; Wachter et
al., Structure 6:1267-1277, 1998; Elsliger et al., Biochemistry 38:5296-5301,
1999). To determine if
the rosGFPs were also pH-sensitive, their absorbance and fluorescence were
scanned over a wide
range of pHs. Figure 8 shows both absorbance and fluorescence excitation
spectra of oxidized
rosGFP2 versus pH. The spectra show that, as the pH is increased from 5.2 up
to 9.0, the
fluorescence intensity of both excitation peaks increases. Plotting the
intensity at 490 nm as a
function of pH and fitting this to a titration curve with a single ionization
constant gave a pKa value
of 6.0 (Figure 9). Titration of rosGFP2 in the reduced state shifted the pKa
to 5.6 (Figure 10).
Initially it appeared that the pH-sensitivity of the rosGFPs might pose a
problem for using
them as tools to determine in vivo redox potentials by introducing pH
artifacts. Therefore, to produce
a pH-insensitive rosGFP, threonine 65 was reverted back to serine, which is
the amino acid found at
this position in wild-type GFP.
Not only did the T65 S reversion completely eliminate pH-sensitivity over the
range of 6 to
8, but it greatly altered the spectral properties of the rosGFPs. Figures 11,
12, and 13 show the
fluorescence excitation spectra of rosGFPl (C48S/S147C/Q204C), rosGFP3
(C48S/N149C/S202C),
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
29
and rosGFP5 (C48S/S147C/N149C/S202C/Q204C) at varying redox potentials. The
most striking
difference between these rosGFPs and threonine 65 containing rosGFPs is the
favoring of band A
over band B fluorescence. There is also a tendency toward more even excitation
of both bands,
which is especially evident in the rosGFP3 and rosGFP5 variants. Unexpectedly,
the T65S reversion
led to a 13-16 mV more reducing redox potential (see Table 5).
Subsequent to construction of the variants containing the T65S reversion, it
was determined
that, by using a fluorescence excitation ratio, any effects induced by pH
changes were virtually
eliminated. Figure 14 illustrates how the ratio of excitation wavelengths
remains a constant over a
large pH range in both the fully reduced or fully oxidized protein. In other
words, the fluorescence
increase due to alkalization or fluorescence decrease upon acidification seen
in the excitation spectra
of rosGFP2 affects the entire spectrum in the same manner, and hence the ratio
of intensities is
unaffected by pH changes in the range of at least pH 6 to 8.5. Therefore, a
ratio of the excitation
wavelengths cancels out variations due to pH fluctuations and allows for redox
status determination
in the absence of pH artifacts.
Since redox reactions involving the liberation of H+ ions are intrinsically
based on pH (see
Example 4), and consequently the pH of the cellular compartment of study must
be determined, the
ability to separate out the pH and redox sensing capabilities of rosGFP2 was
investigated. Excitation
of band A was found to result in pH-dependant dual-emission (Figure 15). In
other words, at low pH,
blue emission prevails and at high pH, green emission dominates, with plus of
5.6 (reduced) to 6.0
(oxidized) dependant upon the redox state of rosGFP2. This phenomenon is a
useful means of
monitoring pH changes in vivo. By utilizing a ratio of emission wavelengths,
pH variations due to
the redox state of the probe are minimized (Figure 16). Therefore, it is
possible to experimentally
separate out the pH and redox contributions to the fluorescent signal, and
thus simultaneous
monitoring of redox and pH is possible with the same probe.
Example 6: Structural Basis for Dual-Excitation
The crystal structure of rosGFP2 was solved in order to better understand how
disulfide
bond formation leads to dual excitation. Crystals belonging to the space group
P21212 were grown of
both the oxidized and reduced forms of rosGFP2 and the crystal structures were
solved by molecular
replacement to 1.9 A and 2.0 A, respectively. The protein crystallized as a
dimer, with three
molecules in the asymmetric unit. One molecule is related to its dimer mate by
a crystallographic
two-fold axis of symmetry, and the other dimer is related to itself by a non-
crystallographic two-fold
axis of symmetry.
Since the resolution limit of the data collected was fairly high, refinement
was performed
without imposing any non-crystallographic symmetry constraints, and thus each
of the three
molecules in the asymmetric unit were independently refined. Analysis of the
different molecules in
the asymmetric unit after refinement revealed only very subtle differences,
all of which were within
experimental error (approximately 0.2 A) for the atomic positions at this
resolution. Interestingly, the
surface facing a solvent channel of one of the molecules comprising the non-
crystallographic
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
symmetry dimer is very poorly ordered. This disorder is most certainly
reflected in many of the
refinement statistics presented in Table 6.
Table 6. Data Collection and Refinement Statistics for
Oxidized and Reduced rosGFP2.
Data Collection
Crystal Oxidized Reduced
Total observations 203,865 194,884
Unique reflections 56,854 38,346
Cell dimensions (a, b, c; A) 186.84, 67.61, 56.08 185.63, 67.86, 56.38
Resolution (A) 29.7-1.90 28.7-2.00
Highest resolution shell (A) 1.95-1.90 2.10-2.00
Completeness' (%) 99.8 (100) 78.2 (74.3)
Multiplicity' 3.6 (3.6) 5.1 (5.5)
Average I/6' 7.2 (2.3) 8.7 (2.2)
Rmergel'2 0.058 (0.247) 0.053 (0.304)
Refinement
Spacegroup P21212 P21212
Number of molecules3 3 3
Number of protein atoms3 5,220 5,216
Number of solvent atoms3 174 132
Rfactor4 0.229 0.223
Average B-factors (A) 46.6 49.7
Protein atoms 46.7 49.7
Solvent 44.2 47.4
rms deviations
Bond lengths (A) 0.020 0.014
Bond angles ( ) 3.111 2.436
B-factor correlations (A) 7.019 5.779
'Values in parentheses indicate statistics for the highest resolution shell.
2Rmerge = EII-<I>I/E <I>, where I is the observed intensity, and <I> is the
average of intensity
obtained from multiple observations of symmetry related reflections.
3Per asymmetric unit.
4Rractor = EIIF0I-IF II/ FIFol,where F0 and F, are the observed and calculated
structure factors,
respectively.
5 The dimer interface is essentially the same as seen for wild-type GFP and
the yellow variant
of GFP (Yang et al., Nature Biotech. 14:1246- 1251, 1996; Wachter et al.,
Structure 6:1267-1277,
1998). One molecule of the dimer is tilted approximately 70 degrees with
respect to the other
molecule based on an imaginary axis drawn from one end of the GFP barrel
structure through the
center and out the other end. The dimer interface is comprised of a small
hydrophobic patch
10 consisting of alanine 206, leucine 221 and phenylalanine 223, a hydrogen
bond interaction between
tyrosine 39 and asparagine 149, as well as a number of hydrophilic contacts
involving several bound
water molecules. At present it is not known whether the dimer is solution
relevant or simply an
artifact created by the crystallization conditions (Palm and Wlodawer, Nat,
Struct. Biol. 4:361-365,
1997). At any rate, knowledge of the dimer interface residues permits future
mutational studies
15 aimed at disrupting dimers without affecting protein stability and folding.
As expected, the introduced cysteines are positioned toward the outside of the
protein and
are in excellent arrangement to form a disulfide bond under oxidizing
conditions. They reside along
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
31
the edge of the dieter interface and adjacent to bulk solvent. The individual
disulfides are separated
by 14 A from the opposing dimer pair of cysteines and therefore, as shown by
gel electrophoresis, are
unable to form intermolecular disulfide bonds and are unlikely to aid in dimer
formation. The
disulfide bond present in the oxidized structure does not have ideal geometry,
with an average Ca-C,.
distance of 4.0 A, Cp-Cp distance of 4.2 A, S-S distance of 2.0 A, Ca Cp-S
angle of 112 , and Cp-S-
S angle of 106 . These parameters diverge from those values seen in other
structures of disulfide
bond-containing proteins (Sowdhamini et al. 1989; Matsumura et al. 1989), and
may also account for
or contribute to the observed spectral perturbations.
Example 7: Mammalian Cell Expression and Fluorescence Microscopy
The mutations C48S/T65S/S147C/Q204C were introduced into the mammalian
expression
plasmid pEGFP-N1 (CLONTECH, Palo Alto, CA). This plasmid has the "folding
mutation" F64L,
which was found not to alter the spectral or redox properties of the rosGFPs.
HeLa cells transiently
transfected with this plasmid using Fugene (Boehringer-Mannheim, Germany) were
imaged one day
post-transfection on a motorized Zeiss Axioscope 2 microscope. The temperature
of the cells was
maintained at 37 C using an open perfusion micro-incubator (Harvard Apparatus
Inc., Holliston,
MA). Dual-excitation ratio imaging required 400(10) and D480/30x excitation
filters, a 505DCXR
dichroic mirror, and a D535/40m emission filter (Edmund Scientific Company,
Omega Optical and
Chroma Technologies, Battleboro, VT) alternated by a fast filter changer.
Images were collected
with a PentaMax cooled CCD camera (Princeton Instruments). Data was collected
and processed
using the program Openlab (Improvision, Lexington, MA).
In vivo Redox Status
To determine if redox-sensitive GFPs work as indicators of redox status within
mammalian
cells, rosGFP1 was expressed in the mitochondria of cultured HeLa cells.
Figure 17 shows the
reticular localization pattern of rosGFP I expressed in the mitochondrial
matrix via fusion at the DNA
level to the mitochondrial targeting sequence of the Ela subunit of pyruvate
dehydrogenase. Upon
addition of an oxidizing agent (H202) the fluorescence excitation ratio (400
net/490 nm) increased, as
expected for an oxidation event (Figure 18). Conversely, the addition of a
reducing agent (DTT)
decreased the elevated ratio to a level below the initial ratio.
From this experiment several things can be concluded. First, rosGFP1 is able
to reversibly
respond to induced redox changes within living cells. As seen in Figure 18,
large fluorescence
changes accompany the addition of H202 or DTT. Second, the results demonstrate
that initially
rosGFPI is not fully reduced or oxidized within mitochondria. Therefore
rosGFP1 is able to detect
the intrinsic redox potential inside mitochondria, presumably by interacting
with endogenous
oxidizing and reducing agents. Moreover, the redox potential ofrosGFPl is
close to that of
mitochondria and hence rosGFP 1 should make an excellent probe for studying
redox changes in
mitochondria. Finally, given the initial fluorescence excitation ratio, the
percentage of reduced to
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
32
oxidized rosGFPI could be estimated and thus the in vivo redox potential of
mitochondria could be
calculated.
Since redox potentials involving the liberation of H} ions are intrinsically
based on pH (see
Example 4), the GFP S65T/H148D variant (Wachter et al., Structure 6:1267-1277,
1998), with a pKa
of 7.8, was used to examine the pH within the mitochondrion. The inherent pH
sensing abilities of
rosGFP2 was not utilized in this instance, due to the high pH nature of
mitochondria and the high
levels of autofluorescence. The fluorescence excitation ratio of GFP
S65T/H148D changed as
function of pH inside the mitochondrial matrix. The addition of oligomycin,
carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP), or hydrochloric acid resulted in an
acidification of the
mitochondrial matrix. On the other hand, addition of NH4CI caused the matrix
pH to increase. From
these types of additions, the resting pH of the mitochondrial matrix of HeLa
cells was estimated to be
7.65 0.15 (n = 110 cells from seven experiments). Due to a slow
acidification process during the'
experimental setup and data collection process, this value may be an
underestimate of the true
mitochondrial matrix pH. Therefore, the pH value of 7.98 0.07 estimated by
Llopis et al. for the
mitochondrial matrix of HeLa cells was used in subsequent calculations (Llopis
et al., Proc. Natl.
Acad. Sci. USA 95:6803-6808, 1998).
Based on an average of 23 cells from seven independent experiments, and
accounting for the
60.2 mV per pH unit change in redox potential for a reaction involving two
protons (see Example 4),
the redox potential in normal resting HeLa cell mitochondria was determined to
be substantially more
reducing than -0.3 V.
To investigate the redox potential of the cytosol, rosGFP2 was expressed in
the cytosol of
HeLa cells. The starting fluorescence amplitude ratio of 400/480 nm excitation
was low, as expected
for the reducing environment of the cytosol of healthy cells. Again, there was
a marked increase and
decrease in the ratio upon addition of H2O2 and DTT, respectively. However the
ratio only recovered
to the starting value, indicating that rosGFP2 was fully reduced in the
cytosol. Hence the redox
potential of the cytosol was estimated to be more reducing than -0.30 V,
assuming a pH of 7.34
(Llopis et al., Proc. Natl. Acad. Sci. USA 95:6803-6808, 1998).
Example 8: Factors that Influence the Redox State of rosGFPs In vivo
It is generally thought that the major redox buffer in cells is glutathione
and that the ratio of
reduced glutathione (GSH) to glutathione disulfide (GSSG) is the crucial
parameter for determining
redox status (Meister, Methods Enzymol. 251:3-7, 1995; Deneke, Curr. Top.
Cell. Regul. 36:151-180,
2000). On average, the ratio of GSH to GSSG is greater than 100:1 for whole
cell determinations on
a wide variety of tissue types and total glutathione levels are believed to be
around 1-10 mM
(Kosower and Kosower, Int. Rev. Cytol. 54:109-160, 1976; Voet and Voet,
Biochemistry, 2nd ed.
John Wiley & Sons, Inc., 1995, New York, NY; Meister, Methods Enzymol. 251:3-
7, 1995). To
investigate whether glutathione may contribute to the redox state of rosGFPs
in vivo, fluorescence
experiments were conducted in vitro.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
33
Incubation of reduced rosGFPl with GSSG resulted in complete oxidation of
rosGFPl in the
absence of air oxidation. From this experiment it was concluded that rosGFPs
expressed in vivo can
be oxidized by GSSG. However, since rosGFPs have a lower affinity for
electrons than does
glutathione, GSH is unable to reduce oxidized rosGFPs.
Several reports agree that the ratio of GSH to GSSG in mitochondria is between
6:1 to 33:1,
with total glutathione approximately 1-2 mM (LeQuoc and LeQuoc, Arch. Biochem.
Biophys.
273:466-478, 1989; Bindoli et al., Arch. Biochem. Biophys. 342:22-28, 1997;
Lenton et al., Anal.
Biochem. 274:125-130, 1999). Substituting these values into the Nernst
equation (assuming a
mitochondrial pH of 7.98, 37 C, and a standard redox potential of-0.205 V
(Szajewski and
Whitesides, J. Am. Chem. Soc. 102:2011-2026, 1980) for the GSH/GSSG couple)
results in a
mitochondrial redox potential in the range of -0.210 to -0.230 V. Since the
redox potential of
mitochondria is estimated to be much more reducing than -0.3 V, glutathione
alone does not appear
to account for such a reducing potential. Therefore, other redox active agents
were investigated.
The NAD+/NADH (nicotinamide adenine dinucleotide) pair was considered, because
it is
present at high concentrations in mitochondria and has a very reducing redox
potential. The ratio of
NAD+ to NADH in the presence or absence of glucose has been estimated to be
anywhere from 1:6 to
10:1 in mitochondria (LeQuoc and LeQuoc, Arch. Biochem. Biophys. 273:466-478,
1989; Ramirez et
al., Biochem. Biophys. Acta 1273:263-267, 1996; Robinson, Methods Enzymol.
264:454-464, 1996).
These ratios translate into redox potentials in the range of-0.328 to -0.382 V
at pH 7.98 and 37 C
using -0.320 V as the standard potential of the NAD+/NADH couple at pH 7. As a
result, this redox
couple appeared to be an ideal candidate for maintaining the very reducing
environment of the
mitochondrion. However, redox reactions involving nicotinamides carry out
concerted two-electron
transfers, whereas thiols undergo two sequential one-electron transfers. As
expected, NADH was
experimentally unable to directly reduce rosGFPI in vitro.
There exists a family of pyridine nucleotide-disulfide oxidoreductases,
comprising
lipoamide dehydrogenases (LDH), glutathione reductases, thioredoxin
reductases, trypanothione
reductase, and alkylhydroperoxide reductase. These enzymes all perform
homologous reactions
ultimately involving the transfer of NADH or NADPH (nicotinamide adenine
dinucleotide
phosphate) reducing equivalents to thiols (Carothers et al., Arch. Biochem.
Biophys. 268:409-425,
1989). In general terms, the reducing equivalents are transferred from NADH or
NADPH through a
concerted two-electron transfer reaction to a bound FAD (flavin adenine
dinucleotide) cofactor. FAD
then reduces a nearby disulfide bridge through two sequential one-electron
transfer reactions. In
some cases, the electrons are transferred by disulfide exchange to other
nearby disulfides (Ellis and
Poole, Biochemistry 36:13349-13356, 1997; Calzi and Poole, Biochemistry
36:13357-13364, 1997).
Finally, the reduced pair of thiols participates in the reduction of a
substrate such as lipoamide,
glutathione, thioredoxin, or one of various peroxides. The key to how these
enzymes carry out their
electron transfer reactions is linked to the chemistry of the FAD cofactor,
which is able to undergo
two sequential one-electron transfers or a simultaneous two-electron transfer.
CA 02440592 2003-09-04
WO 02/077011 PCT/US02/07374
34
To determine if rosGFPs may be in equilibrium with agents other than just
glutathione, an in
vitro system analogous to a portion of the pyruvate dehydrogenase complex was
set up. The system
,consisted of LDH, lipoate, NADH, and oxidized rosGFPl. The rationale behind
this experimental
setup was to monitor the reduction of rosGFP 1 by NADH, through the LDH enzyme
and free lipoic
acid. Figure 19 shows that, with all four components of the system present,
nearly 75% of rosGFPl
is reduced, however removal of LDH, lipoate, or NADH results in less than 5%
reduction of
rosGFP1. Only partial reduction was expected since the redox potential of
rosGFP1 (-0.288 V) and
the lipoic acid/dihydrolipoic acid couple (-0.29 V; Szajewski and Whitesides,
J. Ain. Chem. Soc.
102:2011-2026, 1980) are very similar. Air oxidized and DTT reduced rosGFPI
were used as
standards for obtaining the zero and 100% values. The results of this
experiment indicate that it may
be possible for NADH reducing equivalents, through various enzymes such as
pyruvate
dehydrogenase, to be ultimately imposed on rosGFPs in vivo.
This disclosure provides redox-sensitive green fluorescent proteins (rosGFPs),
nucleic acids
encoding these proteins, and cells transformed with a nucleic acid encoding a
rosGFP. The
disclosure further provides methods of using these molecules to analyze the
redox status of, for
instance, a cell or subcellular compartment. It will be apparent that the
precise details of the methods
described may be varied or modified without departing from the spirit of the
described subject matter.
We claim all such modifications and variations that fall within the scope and
spirit of the claims
below.
CA 02440592 2010-08-17
1
SEQUENCE LISTING
<110> The State of Oregon acting by and through the State Board of Higher
Education on behalf of the University of Oregon
<120> OXIDATION-REDUCTION SENSITIVE GREEN FLUORESCENT PROTEIN VARIANTS
<130> 86479-1
<150> PCT/US02/07374
<151> 2002-03-11
<150> US 60/275,200
<151> 2001-03-12
<150> US 60/293,427
<151> 2001-05-23
<150> US 60/302,894
<151> 2001-07-03
<160> 13
<170> Patentln version 3.1
<210> 1
<211> 238
<212> PRT
<213> Aequorea victoria
<400> 1
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Ser Tyr Gly Val Gin Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gin
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gin Glu Arg
85 90 95
Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Ser Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met Glu Tyr Asn
130 135 140
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
195 200 205
CA 02440592 2010-08-17
2
Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 2
<211> 717
<212> DNA
<213> Artificial Sequence
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
<222> (1)..(717)
<223> amino acid sequence of rosGFP2
<400> 2
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
act tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tgc cac aat gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Cys His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
CA 02440592 2010-08-17
3
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
gtc ctt tta cca gac aac cat tac ctg tcc aca tgc tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Cys Ser Ala Leu Ser
195 200 205
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 3
<211> 238
<212> PRT
<213> Artificial Sequence
<220>
<223> Variant derived from A. victoria
<400> 3
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Cys His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Cys Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
CA 02440592 2010-08-17
4
<210> 4
<211> 717
<212> DNA
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
<222> (1)..(717)
<223> Amino acid sequence of rosGFPl
<400> 4
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
tct tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tgc cac aat gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Cys His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
CA 02440592 2010-08-17
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
gtc ctt tta cca gac aac cat tac ctg tcc aca tgc tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Cys Ser Ala Leu Ser
195 200 205
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 5
<211> 238
<212> PRT
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<400> 5
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Cys His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Cys Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 6
<211> 717
CA 02440592 2010-08-17
6
<212> DNA
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
<222> (1)..(717)
<223> Amino acid sequence of rosGFP4
<400> 6
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
act tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tca cac tgt gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Ser His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
CA 02440592 2010-08-17
7
gtc ctt tta cca gac aac cat tac ctg tgc aca caa tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Gln Ser Ala Leu Ser
195 200 205
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 7
<211> 238
<212> PRT
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<400> 7
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Ser His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Gln Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 8
<211> 717
<212> DNA
<213> Artificial sequence
CA 02440592 2010-08-17
8
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
<222> (1)..(717)
<223> Amino acid sequence of rosGFP3
<400> 8
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
tct tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tca cac tgt gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Ser His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
gtc ctt tta cca gac aac cat tac ctg tgc aca caa tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Gln Ser Ala Leu Ser
195 200 205
CA 02440592 2010-08-17
9
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 9
<211> 238
<212> PRT
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<400> 9
Met Ser Lys Gly Glu Glu Leu Phe Thr G1y Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Ser His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Gln Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 10
<211> 717
<212> DNA
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
CA 02440592 2010-08-17
<222> (1) (717)
<223> Amino acid sequence of rosGFP6
<400> 10
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
act tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tgc cac tgt gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Cys His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
gtc ctt tta cca gac aac cat tac ctg tgc aca tgc tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Cys Ser Ala Leu Ser
195 200 205
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
CA 02440592 2010-08-17
11
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 11
<211> 238
<212> PRT
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<400> 11
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Cys His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Cys Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 12
<211> 717
<212> DNA
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<220>
<221> CDS
<222> (1)..(717)
<223> Amino acid sequence of rosGFP5
CA 02440592 2010-08-17
12
<400> 12
atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att ctt gtt 48
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
gaa tta gat ggt gat gtt aat ggg cac aaa ttt tct gtc agt gga gag 96
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt att tcc 144
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
act act gga aaa cta cct gtt cca tgg cca aca ctt gtc act act ttc 192
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
tct tat ggt gtt caa tgc ttt tca aga tac cca gat cat atg aaa cgg 240
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag gaa aga 288
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
act ata ttt ttc aaa gat gac ggg aac tac aag aca cgt get gaa gtc 336
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa ggt att 384
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
gat ttt aaa gaa gat gga aac att ctt gga cac aaa ttg gaa tac aac 432
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
tat aac tgc cac tgt gta tac atc atg gca gac aaa caa aag aat gga 480
Tyr Asn Cys His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
atc aaa gtt aac ttc aaa att aga cac aac att gaa gat gga agc gtt 528
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
caa cta gca gac cat tat caa caa aat act cca att ggc gat ggc cct 576
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
gtc ctt tta cca gac aac cat tac ctg tgc aca tgc tct gcc ctt tcg 624
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Cys Ser Ala Leu Ser
195 200 205
aaa gat ccc aac gaa aag aga gac cac atg gtc ctt ctt gag ttt gta 672
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
aca get get ggg att aca cat ggc atg gat gaa cta tac aaa taa 717
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
CA 02440592 2010-08-17
13
<210> 13
<211> 238
<212> PRT
<213> Artificial sequence
<220>
<223> Variant derived from A. victoria
<400> 13
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Ser
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Cys His Cys Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Cys Thr Cys Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235
